Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1983 Jul;15(2):121–125. doi: 10.1007/BF00199702

Restoration by levamisole of immune responses suppressed in tumor-bearing mice

Morio Shiraishi 1,✉, Kunisuke Himeno 1, Kikuo Nomoto 1
PMCID: PMC11039215  PMID: 6553512

Abstract

Restorative effects of levamisole on suppressed immune responses were observed in BALB/c mice inoculated with a syngeneic methylcholanthrene-induced fibrosarcoma and immunized with nucleated chicken erythrocytes. In tumor-bearing mice, cell-mediated cytotoxicity, delayed footpad reaction, and antibodies were suppressed, and only the delayed footpad reaction was restored by levamisole. Suppressive effects in tumor-bearing mice can be transferred with sera or spleen cells, and the expression of suppressive effects cannot be abolished by treatment of the recipients with levamisole. However, the generation of suppressor mechanisms was affected by treatment of tumor-bearing donors with levamisole.

Keywords: Immune Response, Cancer Research, Suppressive Effect, Spleen Cell, Levamisole

References

  • 1.Al-Ibrahim MS, Holzman RS, Lawrence HS. Levamisole concentrations required for enhanced proliferation of human lymphocytes and phagocytosis by macrophage. J Infect Dis. 1977;135:517–523. doi: 10.1093/infdis/135.4.517. [DOI] [PubMed] [Google Scholar]
  • 2.Brugmas J, Schuermans V, DeCock W, Thienport D, Janssen P, Verhaegen H, van Nimmen L, Louwagine AC, Stevens E. Restration of host defense mechanisms in man by levamisole. Life Sci. 1973;13:1499–1504. doi: 10.1016/0024-3205(73)90137-9. [DOI] [PubMed] [Google Scholar]
  • 3.Chan SH, Simons MJ. Levamisole and lymphocyte responsiveness. Lancet. 1975;I:1246–1247. doi: 10.1016/s0140-6736(75)92243-6. [DOI] [PubMed] [Google Scholar]
  • 4.Chirigos MA, Pearson JW, Pryor J. Augmentation of chemotherapeutically induced remission of a murine leukemia by a chemical immuno-adjuvant. Cancer Res. 1973;33:2615–2618. [PubMed] [Google Scholar]
  • 5.DeCree J, Verhaegen H, DeCock W, et al. Impaired neutrophil phagocytosis. Lancet. 1974;II:294–295. doi: 10.1016/s0140-6736(74)91464-0. [DOI] [PubMed] [Google Scholar]
  • 6.Dinai Y, Pras M. Levamisole in rheumatoid arthritis. Lancet. 1975;II:556. doi: 10.1016/s0140-6736(75)90934-4. [DOI] [PubMed] [Google Scholar]
  • 7.Fidler IJ, Spetler LE. Effects of levamisole on in vivo and in vitro murine host response on syngeneic transplantable tumor. J Natl Cancer Inst. 1975;55:1107–1112. doi: 10.1093/jnci/55.5.1107. [DOI] [PubMed] [Google Scholar]
  • 8.Hodden JW, Coffey RG, Hodden EM, Lopes-Corrales E, Suvshine GH. Effects of levamisole and imidazole on lymphocytoproliferation and cyclic nucleotide levels. Cell Immunol. 1975;20:98–103. doi: 10.1016/0008-8749(75)90088-x. [DOI] [PubMed] [Google Scholar]
  • 9.Hoebeke J, Franchi G. Influence of tetramisole and its optical isomers on the mononuclear phagocytic system: Effect on carbon clearance in mice. J Reticuloendoth Soc. 1973;14:317–323. [PubMed] [Google Scholar]
  • 10.Johnson RK, Houchens DP, Gaston MR, Goldin A. Effects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems. Cancer Chemother Rep. 1975;59:697–705. [PubMed] [Google Scholar]
  • 11.Kubo C, Nomoto K, Sato M, Takeya K. Direct cytotoxicity against chicken erythrocytes in mice. I. Fundamental nature of T cell-mediated cytotoxicity. Immunology. 1977;33:895–905. [PMC free article] [PubMed] [Google Scholar]
  • 12.Levo T, Ratler V, Ramot B. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease. Biomedicine. 1975;23:198–200. [PubMed] [Google Scholar]
  • 13.Lichtenfeld JL, Desner MR, Maridney MR, Jr, Wiernik PH. Amplification of immunologically induced lymphocyte 3H-thymidine incorporation by levamisole. Fed Proc. 1974;33:790. [Google Scholar]
  • 14.Lichtenfeld JL, Cesner MR, Wiernik PH, Mardiney MR, et al. Modulating effects of levamisole (NSC-177023) on human lymphocyte response in vitro. Cancer Treat Rep. 1976;60:571–574. [PubMed] [Google Scholar]
  • 15.Lima AO, Javierre MQ, da Silva WD, et al. Immunological phagocytosis: Effects of drugs on phosphodiesterase activity. Experientia. 1974;30:945–946. doi: 10.1007/BF01938377. [DOI] [PubMed] [Google Scholar]
  • 16.Mantovani A, Spreafico F. Allgeneic tumor enhancement by levamisole, a new immunostimulatory compound: Studies on cell-mediated immunity and humoral antibody response. Eur J Cancer. 1975;11:537–544. doi: 10.1016/0014-2964(75)90125-5. [DOI] [PubMed] [Google Scholar]
  • 17.Okuda S, Kubo C, Taniguchi K, Nomoto K. Different susceptibility of various immune reactions to suppressive effect in the tumor bearing state. Cancer Immnol Immunother. 1980;9:87. [Google Scholar]
  • 18.Pabst HF, Crawford J. l-Tetramisole, enhancement of human lymphocyte response to antigen. Clin Exp Immunol. 1975;21:468–473. [PMC free article] [PubMed] [Google Scholar]
  • 19.Ramot B, Biniaminov M, Shoham C, Rosenthal E. Effect of levamisole on E-rosett-forming cells in vivo and in vitro in Hodgkin's disease. N Engl J Med. 1976;294:809–811. doi: 10.1056/NEJM197604082941504. [DOI] [PubMed] [Google Scholar]
  • 20.Renoux G, Renoux M. Antigenic competition and nonspecific immunity after a Richettsial infection in mice: Restoration of antibacterial immunity by phenylimidothiazole treatment. J Immunol. 1972;109:761–765. [PubMed] [Google Scholar]
  • 21.Renoux G, Renoux M. Levamisole inhibits and cures a solid malignant tumour and its pulmonary metastasis in mice. Nature New Biol. 1972;240:217–218. doi: 10.1038/newbio240217a0. [DOI] [PubMed] [Google Scholar]
  • 22.Renoux G, Renoux M. Modulation of immune reactivity by phenylimidothiazole salts in mice immunized by sheep red blood cells. J Immunol. 1974;113:779–790. [PubMed] [Google Scholar]
  • 23.Renoux G, Renoux M, Pabst A (1975) Influences of levamisole on T-cell reactivity and on survival of untractable cancer patients. Second Conference of Modulation on Host Immune Resistance in the Prevention or Treatment of Induced Neoplasias: U.S. Govt. Printing Office, Washington Fogarty International Center Proceedings no. 28
  • 24.Rojas AF, Feierstein JN, Mickiewicz E, Glait H, Olivare AJ. Levamisole advanced human breast cancer. Lancet. 1976;I:211–215. doi: 10.1016/s0140-6736(76)91337-4. [DOI] [PubMed] [Google Scholar]
  • 25.Sadowski JW, Rapp F. Inhibition by levamisole of metastases by cells transformed by herpes simplex virus type 1 (38776) Proc Soc Expl Biol Med. 1975;149:219–222. doi: 10.3181/00379727-149-38776. [DOI] [PubMed] [Google Scholar]
  • 26.Sampson D, Peters TG, Lewis TD, Metzig J, Kurtz BE. Dose dependence of immunopotentiation and tumor regression induced by levamisole. Cancer Res. 1977;37:3526–3529. [PubMed] [Google Scholar]
  • 27.Tripodi D, Parks LC, Brugmons J. Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N Engl J Med. 1973;289:354–357. doi: 10.1056/NEJM197308162890707. [DOI] [PubMed] [Google Scholar]
  • 28.Verhaegen H, DeCock W, DeCree J, Verbruggen F, Verhaegen-Declerq M, Brugmas J. In vitro restoration by levamisole of thymus-derived lymphocyte function in Hodgkin's disease. Lancet. 1975;I:978. doi: 10.1016/s0140-6736(75)92040-1. [DOI] [PubMed] [Google Scholar]
  • 29.Webster DJT, Hughes LE. Levamisole. Lancet. 1975;I:917–918. doi: 10.1016/s0140-6736(75)91715-8. [DOI] [PubMed] [Google Scholar]
  • 30.Woods WA, Fliegelman MJ, Chirigos MA. Effect of levamisole (NSC-177023) on DNA synthesis by lymphocytes from immunosuppressed C57BL mice. Cancer Chemother Rep. 1975;59:531–536. [PubMed] [Google Scholar]
  • 31.Woods WA, Fliegelman MJ, Chirigos MA. Effect of levamisole on the in vitro immune response of spleen lymphocytes. Proc Soc Exp Med. 1975;148:1048–1050. doi: 10.3181/00379727-148-38686. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES